MedTrace Logo

Pharmacokinetic Study of Two Oral Bemiparin Formulations

NCT00863577 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2011-03-18

No results posted yet for this study

Summary

The primary pharmacokinetic analysis will be the correlation of the AUC amidolytic anti-Xa activity

Conditions

  • Healthy

Interventions

DRUG

Oral bemiparin

Bemiparin tablets and bemiparin tablets into hard gelatine capsules

Sponsors & Collaborators

  • Rovi Pharmaceuticals Laboratories

    lead INDUSTRY

Study Design

Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2010-12-31
Completion
2011-01-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00863577 on ClinicalTrials.gov